ライフサイエンスコーパス: ziprasidone

1 liorated by clozapine but not haloperidol or ziprasidone.

2 idepressant efficacy also favored adjunctive ziprasidone.

3 ne, olanzapine, quetiapine, risperidone, and ziprasidone.

4 ment, in patients treated with quetiapine or ziprasidone.

5 eridone, and 79 percent of those assigned to ziprasidone.

6 ilar to that of quetiapine, risperidone, and ziprasidone.

7 efficacy versus haloperidol, quetiapine, and ziprasidone.

8 these variables were significant and favored ziprasidone.

9 r other safety parameters were observed with ziprasidone.

10 ped antipsychotic drugs, e.g., clozapine and ziprasidone.

11 -0.14), olanzapine (-0.25, -0.39 to -0.12), ziprasidone (-0.25, -0.48 to -0.01), and risperidone (-0

12 : haloperidol, -1.0 (IQR, -28.0 to 15.0) ms; ziprasidone, 0 (IQR, -23.0 to 20.0) ms; and placebo, -3.

13 14.0 [6.0-18.0] days) as did patients in the ziprasidone (15.0 [9.1-18.0] days) and placebo groups (1

14 mg; sertindole, 22.5 mg/day and 3.6 mg; and ziprasidone, 186 mg/day and 30 mg.

15 onths) than with quetiapine (4.0 months) and ziprasidone (2.8 months).

16 , quetiapine=125, risperidone=124, UC=30 and ziprasidone=32), 4 of which were conference abstracts an

17 Ziprasidone (40 to 160 mg per day) was included after it

18 io to 3 weeks of double-blind treatment with ziprasidone (40-80 mg twice daily) or placebo.

19 =63]; risperidone, 1.5-6.0 mg/day [N=69]; or ziprasidone, 40-160 mg/day [N=135]).

20 r: haloperidol, 458.0 (IQR, 432.0-479.0) ms; ziprasidone, 451.0 (IQR, 424.0-472.0) ms; and placebo, 4

21 ne, quetiapine, olanzapine, risperidone, and ziprasidone all potently antagonize the beta-arrestin 2

22 antly increased with olanzapine but not with ziprasidone; all between-group comparisons of these vari

23 mean daily doses were 129.9 mg (SD=27.3) for ziprasidone and 11.3 mg (SD=2.8) for olanzapine.

24 During 6 weeks' treatment, ziprasidone and olanzapine demonstrated comparable antip

25 pared 1-year mortality rates associated with ziprasidone and olanzapine in real-world use.

26 rs compared the efficacy and tolerability of ziprasidone and olanzapine in the treatment of acutely i

27 le and CGI severity scale scores between the ziprasidone and placebo groups.

28 gs (olanzapine, quetia-pine, risperidone, or ziprasidone) and followed for up to 18 months.

29 n, including thioridazine, mesoridazine, and ziprasidone, and for monitoring for signs of myocarditis

30 apine was more effective than quetiapine and ziprasidone, and risperidone was more effective than que

31 66 risperidone, olanzapine, quetiapine, and ziprasidone arms including 7264 patients.

32 Ziprasidone as an adjunct to escitalopram demonstrated a

33 pine were more effective than quetiapine and ziprasidone as reflected by longer time until discontinu

34 idone, olanzapine, quetiapine, aripiprazole, ziprasidone, asenapine, iloperidone, or paliperidone) wi

35 y evaluated the efficacy and tolerability of ziprasidone, compared with placebo, in the treatment of

36 Ziprasidone does prolong the QT interval, but there is n

37 ssigned in a 1:1 ratio to receive adjunctive ziprasidone (escitalopram plus ziprasidone, N=71) or adj

38 e, perphenazine, quetiapine, risperidone, or ziprasidone for up to 18 months.

39 The escitalopram plus ziprasidone group also showed significantly greater impr

40 sia, compared with six (20%) patients in the ziprasidone group and seven (19%) patients in the placeb

41 Ten (14%) patients in the escitalopram plus ziprasidone group discontinued treatment because of into

42 nificantly greater for the escitalopram plus ziprasidone group.

43 one, quetiapine, risperidone, valproate, and ziprasidone had lower discontinuation due to inefficacy

44 ne, quetiapine, olanzapine, risperidone, and ziprasidone, have been reported to preferentially increa

45 oral aripiprazole (hazard ratio=1.14), oral ziprasidone (hazard ratio=1.13), and oral quetiapine (ha

46 Ziprasidone hydrochloride was included after its approva

47 rs sought to test the efficacy of adjunctive ziprasidone in adults with nonpsychotic unipolar major d

48 red olanzapine, quetiapine, risperidone, and ziprasidone in patients who had just discontinued a diff

49 with olanzapine, quetiapine, risperidone, or ziprasidone in phase 1 or 1B of the trials, primarily be

50 e findings of this study failed to show that ziprasidone is associated with an elevated risk of nonsu

51 Only widespread use will prove if ziprasidone is entirely safe.

52 Ziprasidone, like many BCS Class II drugs with low intri

53 Ziprasidone monotherapy was significantly superior to pl

54 ts were randomized to haloperidol (n = 192), ziprasidone (n = 190), or placebo (n = 184).

55 , patients were randomly assigned to receive ziprasidone (N=136) or olanzapine (N=133).

56 r of initiating pharmacotherapy was 0.91 for ziprasidone (N=9,077) and 0.90 for olanzapine (N=9,077).

57 ve adjunctive ziprasidone (escitalopram plus ziprasidone, N=71) or adjunctive placebo (escitalopram p

58 The Ziprasidone Observational Study of Cardiac Outcomes (ZOD

59 apine (odds ratio: 1.56, 95% CI: 1.47-1.67), ziprasidone (odds ratio: 1.40, 95% CI: 1.19-1.65), and f

60 , N=386), amisulpride (one study, N=331), or ziprasidone (one study, N=207) for a weighted mean and m

61 ly assigned to receive treatment with either ziprasidone or olanzapine and followed for 1 year by unb

62 randomly assigned to receive haloperidol or ziprasidone or placebo every 6 hrs for up to 14 days.

63 [OR], 0.95; 95% CI, 0.66-1.37; P = .78) nor ziprasidone (OR, 1.09; 95% CI, 0.75-1.57; P = .78) was a

64 , the risk was higher among those initiating ziprasidone (OR, 1.61; 95% CI, 0.99-2.64; P = .06) and a

65 delirium randomized to receive haloperidol, ziprasidone, or placebo.

66 randomized 1:1:1 to intravenous haloperidol, ziprasidone, or saline placebo administered twice daily

67 e-LAI, aripiprazole-OS, paliperidone-OS, and ziprasidone-OS.

68 pine, risperidone, tamoxifen, valproate, and ziprasidone outperformed response to treatment (N = 56,

69 pine, risperidone, tamoxifen, valproate, and ziprasidone outperformed the improvement of mania sympto

70 0.26 for risperidone (P<.001), and 0.12 for ziprasidone (P<.06), with no significant differences bet

71 up, but not in the perphenazine (P=0.021) or ziprasidone (P=0.028) group.

72 Ziprasidone produced rapid, sustained improvements relat

73 nzapine was on average more efficacious than ziprasidone (standardized mean difference, SMD=0.37, 95%

74 brexpiprazole, cariprazine, lurasidone, and ziprasidone the most benign profiles.

75 4.58 kg (95% CI: -5.33 to -3.83) compared to ziprasidone to -2.30 kg (95% CI: -3.35 to -1.25) compare

76 ipants) ranged from -0.16 kg (-0.73 to 0.40; ziprasidone) to 3.21 kg (2.10 to 4.31; zotepine), for pr

77 e.g. clozapine, risperidone, olanzapine and ziprasidone, to improve cognitive function in schizophre

78 pite the known risk of QTc prolongation with ziprasidone treatment, the findings of this study failed

79 Quetiapine, risperidone, and ziprasidone use were not associated with the warning.

80 lafaxine, bupropion, quetiapine, olanzapine, ziprasidone, valproic acid, carbamazepine, and citalopra

81 der adults with schizophrenia, intramuscular ziprasidone was found to be effective, and evidence is e

82 set of action was rapid, and tolerability of ziprasidone was generally comparable to that of placebo.

83 Ziprasidone was well tolerated and associated with a low

84 Olanzapine, but not ziprasidone, was associated with significant increases i

85 Differences favoring ziprasidone were observed in metabolic parameters.

86 long-acting injection (risperidone LAI), and ziprasidone--were used to identify a cohort of 24 FDA-re

87 ole, lurasidone, olanzapine, quetiapine, and ziprasidone) with lithium or valproate (LIT/VAL) compare